Review
Oncology
Cynthia Aristei, Elisabetta Perrucci, Emanuele Ali, Fabio Marazzi, Valeria Masiello, Simonetta Saldi, Gianluca Ingrosso
Summary: Breast cancer, as the most common malignancy in women, requires personalized treatment approaches in radiation oncology. While systemic therapies based on molecular subtypes are personalized, personalized radiation therapy is still in development to better tailor treatment and improve outcomes. Efforts are being made to identify prognostic factors and biomarkers for personalized radiation therapy selection.
FRONTIERS IN ONCOLOGY
(2021)
Review
Health Care Sciences & Services
Mohammad Raad, William Omar Contreras Lopez, Alireza Sharafshah, Marjan Assefi, Kai-Uwe Lewandrowski
Summary: This study systematically reviewed the latest research progress in cancer pain management, highlighting personalized medicine as one of the most promising strategies. By utilizing genomic and pharmacokinetic approaches, genes and variants associated with cancer pain can be identified, providing guidance for clinical personalized treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Health Care Sciences & Services
Michael Kenn, Rudolf Karch, Dan Cacsire Castillo-Tong, Christian F. Singer, Heinz Koelbl, Wolfgang Schreiner
Summary: The presence or absence of estrogen and progesterone receptors is an important biomarker for therapy selection in breast cancer patients. Conventional immunohistochemistry measurement has errors, and there have been attempts to increase precision by incorporating gene expression information. Dempster-Shafer decision theory (DST) is a suitable approach for dealing with contradicting evidence obtained through different techniques. This study compares DST with classical statistics in the context of breast cancer patient data, aiming to demonstrate the potential applications of DST in medicine.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Fangyoumin Feng, Bihan Shen, Xiaoqin Mou, Yixue Li, Hong Li
Summary: The response rate of most anti-cancer drugs is limited due to cancer heterogeneity and complex drug mechanisms. Personalized treatment using molecular biomarkers shows promise. Advances in pharmacogenomics, especially computational methods in drug response prediction, have been successful and increasingly utilized in personalized cancer medicine.
JOURNAL OF GENETICS AND GENOMICS
(2021)
Article
Oncology
Natalie M. Reizine, Peter H. O'Donnell
Summary: The integration of genomic data into personalized treatment planning has transformed oncology care. Pharmacogenomics seeks to identify genetic variants that influence an individual's unique drug response. Both somatic and germline genomic information can benefit cancer patients by informing treatment planning and assessing toxicity risk.
CA-A CANCER JOURNAL FOR CLINICIANS
(2022)
Article
Pharmacology & Pharmacy
Michelle Whirl-Carrillo, Rachel Huddart, Li Gong, Katrin Sangkuhl, Caroline F. Thorn, Ryan Whaley, Teri E. Klein
Summary: Clinical annotations in PharmGKB summarize the association between variant-drug pairs and are assigned a level of evidence. To ensure consistency and transparency, a scoring system has been developed to automate LOE assignment. This system improves the quality and reliability of clinical annotations.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pathology
Bashdar Mahmud Hussen, Sara Tharwat Abdullah, Abbas Salihi, Dana Khdr Sabir, Karzan R. Sidiq, Mohammed Fatih Rasul, Hazha Jamal Hidayat, Soudeh Ghafouri-Fard, Mohammad Taheri, Elena Jamali
Summary: Next-generation sequencing (NGS) has become increasingly popular in genomics studies due to advancements in sequencing technology. It is now being utilized in clinical oncology to improve cancer therapy through various approaches, including finding cancer mutations, identifying carriers of these mutations, and implementing personalized medicine. Personalized medicine has the potential to reduce medical expenses by shifting towards an individualized preventive and predictive approach. NGS can accelerate early disease diagnosis and discover pharmacogenetic markers that aid in personalized therapies. Additionally, NGS provides a more comprehensive understanding of cancer and uncovers pathways of cancer development.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Review
Biochemistry & Molecular Biology
Perez-De Marcos Juan-Carlos, Perez-Pineda Perla-Lidia, Mendez-Morales Stephanie-Talia, Arellano-Mendoza Monica-Griselda, Torres-Espindola Luz-Maria
Summary: The ATP binding-cassette superfamily, mostly transmembrane transporters found in humans, plays a key role in regulating various physiological functions and is associated with multidrug resistance and pharmacological response regulation.
MOLECULAR BIOLOGY REPORTS
(2021)
Article
Health Care Sciences & Services
Himesh B. Zaver, Hassan Ghoz, Balkishan Malviya, Aman Bali, Samuel Antwi, Ann M. Moyer, Yan Bi
Summary: The study aimed to evaluate the potential role of inherited polymorphisms of drug-metabolizing enzymes, CYP3A4 and CYP3A5, in sedation requirements for outpatient endoscopic procedures. A retrospective analysis of sedation requirements and pharmacogenomics data in 106 patients who underwent outpatient esophagogastroduodenoscopy or colonoscopy was conducted. The results showed that patients with reduced metabolism of certain enzymes were more likely to require normal sedation during outpatient endoscopic procedures. Therefore, understanding the inter-individual variation in CYP450 genes may be helpful in determining sedation requirements for outpatient endoscopic procedures.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Charalabos Antonatos, Paschalia Asmenoudi, Mariza Panoutsopoulou, Yiannis Vasilopoulos
Summary: The emergence of high-throughput approaches in personalized medicine has greatly enhanced our understanding of inheritable variation and facilitated the identification of response biomarkers. The utilization of pharmaco-omics data has allowed for the discovery of key molecular biomarkers that can predict treatment response, optimizing therapy and enabling tailored treatment plans.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Fabrice Andre, Thomas Filleron, Maud Kamal, Fernanda Mosele, Monica Arnedos, Florence Dalenc, Marie-Paule Sablin, Mario Campone, Herve Bonnefoi, Claudia Lefeuvre-Plesse, William Jacot, Florence Coussy, Jean-Marc Ferrero, George Emile, Marie-Ange Mouret-Reynier, Jean-Christophe Thery, Nicolas Isambert, Alice Mege, Philippe Barthelemy, Benoit You, Nawale Hajjaji, Ludovic Lacroix, Etienne Rouleau, Alicia Tran-Dien, Sandrine Boyault, Valery Attignon, Pierre Gestraud, Nicolas Servant, Christophe Le Tourneau, Linda Larbi Cherif, Isabelle Soubeyran, Filippo Montemurro, Alain Morel, Amelie Lusque, Marta Jimenez, Alexandra Jacquet, Anthony Goncalves, Thomas Bachelot, Ivan Bieche
Summary: Cancer progression is driven by genomic alterations. Genomic profiling can help select effective therapies. A study on HER2-non-overexpressing metastatic breast cancer patients showed that targeted therapies matched to genomic alterations can improve progression-free survival, especially for patients with BRCA1/2 mutations.
Article
Biochemistry & Molecular Biology
Barbara Costa, Nuno Vale
Summary: Breast cancer is a heterogeneous disease with four major molecular subtypes, which have different risk profiles and treatment methods. Early detection improves treatment prospects, but some early-stage patients still face metastasis or resistance to chemotherapy. Immunotherapy is a promising option, but only a small subset of patients respond well in the long term. Current strategies focus on histopathological examination and molecular diagnosis, neglecting the tumor microenvironment and microbiome. Utilizing pharmacogenomics and pharmacomicrobiomics can identify potential biomarkers for real-time therapy guidance and monitoring, considering drug metabolism and its relationship with the microbiome.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Mariana Babayeva, Zvi G. Loewy
Summary: Cannabis and related compounds have gained significant research interest as a potential therapeutic option. However, determining the individual therapeutic effects and side effects of cannabinoids remains challenging. Pharmacogenomics offers a possible solution by identifying genetic variations that contribute to interpatient variability in cannabis response. This review provides an overview of current knowledge on pharmacogenomics associated with medical marijuana and related compounds, with the aim of improving treatment outcomes and reducing adverse effects.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2023)
Review
Medicine, General & Internal
Alireza Tafazoli, Natalia Wawrusiewicz-Kurylonek, Renata Posmyk, Wojciech Miltyk
Summary: Pharmacogenomics, based on genomic profiles, is crucial for understanding diverse drug responses and effects in individuals, leading towards personalized medicine. Although next generation sequencing methods have provided genetic data for common medicines, the lack of clear guidelines for utilizing this data in routine treatment decisions remains a challenge.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Information Science & Library Science
Wei Chen, Yixin Lu, Liangfei Qiu, Subodha Kumar
Summary: Breast cancer remains a leading cause of cancer deaths among women globally, with contemporary treatment being complex and requiring highly specialized medical professionals. This research proposes a novel framework for decision support in treatment planning for early stage breast cancer patients undergoing radiotherapy, which consistently outperforms existing practices in simulation experiments. Our study contributes to the potential of healthcare information technologies in delivering cost-effective care and provides pragmatic models and tools for clinical care delivery systems.
INFORMATION SYSTEMS RESEARCH
(2021)